Positive Data Available from Phase 4 Trial for Primary Immunodeficiencies
allinonemovie / Pixabay

Positive Data Available from Phase 4 Trial for Primary Immunodeficiencies

  In a late July 2023 news release, global healthcare company Grifols shared that positive topline data was now available from a Phase 4 clinical study evaluating XEMBIFY (immune globulin…

Continue Reading Positive Data Available from Phase 4 Trial for Primary Immunodeficiencies
Could Melanoma Drugs be Effective in Treating Papillary Craniopharyngioma (PCP)?
source: pixabay.com

Could Melanoma Drugs be Effective in Treating Papillary Craniopharyngioma (PCP)?

  Each year, there are less than 600 new cases of papillary craniopharyngioma (PCP) diagnosed within the United States. While PCP typically has a good prognosis with treatment, treatment is…

Continue Reading Could Melanoma Drugs be Effective in Treating Papillary Craniopharyngioma (PCP)?
Positive Topline Data Available on ALTB-268 for Ulcerative Colitis 
https://pixabay.com/en/anatomical-anatomy-body-gut-health-2261006/

Positive Topline Data Available on ALTB-268 for Ulcerative Colitis 

  In a Phase 1 clinical study, researchers wanted to understand whether ALTB-268, developed by clinical-stage biotechnology company AltruBio Inc., could be effective in treating ulcerative colitis. The study first…

Continue Reading Positive Topline Data Available on ALTB-268 for Ulcerative Colitis 
Phase 3 Trial Evaluating Magrolimab Combo for MDS Discontinued for Futility
source: shutterstock.com

Phase 3 Trial Evaluating Magrolimab Combo for MDS Discontinued for Futility

In 2020, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to magrolimab for the treatment of newly diagnosed myelodysplastic syndromes (MDS). This designation is designed to expedite…

Continue Reading Phase 3 Trial Evaluating Magrolimab Combo for MDS Discontinued for Futility
Positive Topline Data Available on VYVGART Hytrulo for People Living with CIDP
https://pixabay.com/photos/hospital-infusion-hand-association-834157/

Positive Topline Data Available on VYVGART Hytrulo for People Living with CIDP

  In June 2023, the U.S. Food and Drug Administration (FDA) approved the use of VYVGART Hytrulo for people living with generalized myasthenia gravis (gMG), a chronic autoimmune neuromuscular disease…

Continue Reading Positive Topline Data Available on VYVGART Hytrulo for People Living with CIDP
Improving Screening for Barrett’s Esophagus Could Contribute to Earlier Esophageal Cancer Identification
source: pixabay.com

Improving Screening for Barrett’s Esophagus Could Contribute to Earlier Esophageal Cancer Identification

Barrett's esophagus is a condition in which the esophagus, or the tube that connects the mouth to the stomach, becomes damaged, typically due to long-term exposure to stomach acid; this…

Continue Reading Improving Screening for Barrett’s Esophagus Could Contribute to Earlier Esophageal Cancer Identification
Certain Antibiotics Associated with Higher GvHD Risk Following Allo-HCT
[Source: pixabay.com]

Certain Antibiotics Associated with Higher GvHD Risk Following Allo-HCT

  Following allogeneic hematopoietic stem cell transplant (allo-HCT), which uses healthy stem cells from a donor, many doctors prescribe antibiotics to patients as a protective measure. Many individuals become neutropenic…

Continue Reading Certain Antibiotics Associated with Higher GvHD Risk Following Allo-HCT
ICYMI: Enrollment Began in June for Hypoparathyroidism Natural History Study
mohamed_hassan / Pixabay

ICYMI: Enrollment Began in June for Hypoparathyroidism Natural History Study

How does hypoparathyroidism evolve and progress over time? Are available treatment and management strategies providing efficacious disease control? What are the long-term effects of hypoparathyroidism on overall health—and are there…

Continue Reading ICYMI: Enrollment Began in June for Hypoparathyroidism Natural History Study
Study Found Ziritaxestat Ineffective in Improving IPF Lung Function
source: pixabay.com

Study Found Ziritaxestat Ineffective in Improving IPF Lung Function

Both Ofev (nintedanib) and Esbriet (pirfenidone) are FDA-approved to treat individuals living with mild, moderate, or severe idiopathic pulmonary fibrosis (IPF). The treatments work by preventing fibrosis (scarring) and stopping…

Continue Reading Study Found Ziritaxestat Ineffective in Improving IPF Lung Function
Adding Evinacumab to Care Plan Can Significantly Increase HoFH Life Expectancy
https://pixabay.com/en/doctor-blood-life-veins-pain-2346235/

Adding Evinacumab to Care Plan Can Significantly Increase HoFH Life Expectancy

In the average person, you would expect to see normal to near-optimal low-density lipoprotein (LDL) cholesterol levels sitting at 129 mg/DL or lower; levels under 100 are seen as healthier.…

Continue Reading Adding Evinacumab to Care Plan Can Significantly Increase HoFH Life Expectancy